Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

51results about How to "Inhibition of newborns" patented technology

Transfer RNA fragments and application thereof

The invention discloses multiple transfer RNA fragments which derive from the following fragments with full-length sequences and containing 20-55 nucleotides: tRNA-val, tRNA-gly, tRNA-glu or tRNA-his, wherein the full-length sequence of tRNA-val is shown in SEQ ID NO 1, the full-length sequence of tRNA-gly is shown in SEQ ID NO 2, the full-length sequence of tRNA-glu is shown in SEQ ID NO 3, and the full-length sequence of tRNA-his is shown in SEQ ID NO 4. The transfer RNA fragments can be used for treating tumors and regulating angiogenesis.
Owner:上海市第六人民医院东院 +1

Anti-VEGF/ANG2 bispecific antibody, and application thereof

The invention relates to bispecific monoclonal antibody medicaments, and especially relates to a human vascular endothelial growth factor (VEGF / VEGF-A) resistant and human angiopoietin 2 (ANG2) resistant bispecific monoclonal antibody medicine, which is used for resisting neovascularization. The anti-VEGF / ANG2 bispecific antibody is characterized in that: a VEGF monoclonal antibody is adopted as a basis, and a second antigen binding site is replaced by an antibody segment specifically bound to ANG2.
Owner:CHANGZHOU ADAM BIOTECH

Application of blood vessel inhibiting polypeptides with integrin affinity and bonding capability and MMPs (matrix metalloproteinases) inhibiting capability

The invention discloses an application of a blocker with integrin affinity and bonding capability and MMPs (matrix metalloproteinases) inhibiting capability, and belongs to the field of medicines. The application comprises a polypeptide I (Arg-Gly-Asp-Gly-Gly-Gly-Gly-Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu) and a polypeptide II (Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu-Gly-Gly-Gly-Gly-Arg-Gly-Asp), wherein the polypeptide I is modified with an integrin ligand sequence (Arg-Gly-Asp-Gly-Gly-Gly-Gly); two types of blood vessel inhibiting polypeptides with integrin affinity and bonding capability are formed. The application has the advantages that because of the targeting property of an RGD (arginine-glycin-aspartate) sequence, the polypeptides can be targeted to the new blood vessel endothelium of the RA (rheumatoid arthritis) pannus forming process, the forming of MMPs (matrix metalloproteinases) and the new blood vessel can be inhibited, and the effect of preventing or treating the blood vessel and inflammatory diseases are realized; the polypeptides can be applied to the treatment of the blood vessel and inflammatory diseases, such as arthritis, inflammation, tumors, and eye diseases.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD

Polypeptide CKA18N for inhibiting angiogenesis and application thereof

The invention discloses a polypeptide CKA18N and application of the polypeptide CKA18N or pharmaceutically acceptable salt thereof to preparation of drugs for treating and / or preventing diseases caused by angiogenesis. The polypeptide CKA18N has an amino acid sequence which has a sequence consistency of 13.18 or more when being compared with SEQ ID NO. 1. The invention furthermore discloses a pharmaceutical composition for treating diseases caused by angiogenesis; and the pharmaceutical composition comprises the polypeptide CKA18N, or the pharmaceutically acceptable salt of the polypeptide CKA18N, and a pharmaceutically acceptable carrier. Compared with the existing drugs for inhibiting angiogenesis, the polypeptide CKA18N (SEQ ID NO. 1) has the following advantages: (1) the CKA18N is as long as 18 amino acids, is easy to synthesize and low in cost; (2) the polypeptide CKA18N has a remarkable effect of inhibiting angiogenesis; and (3) the polypeptide CKA18N has relatively good solubility in water and is easily administered by injection.
Owner:LINK HEALTH GRP

Human angiogenin antisense oligonucleotide and medicine combination

An antisense oligonucleotide for suppressing the synthesis of human endogenous angiogenin and its medicine composition are disclosed. The said antisense oligonucleotide can act on the mRNA of endogenous angiogenin, so suppressing its synthesis and the growth of tumor cells.
Owner:上海福缘生化药学研发有限公司

Anti-tumor vascular drug sustained-release embolization microsphere for malignant tumor interventional therapy

The invention discloses an anti-tumor vascular drug sustained-release embolization microsphere for malignant tumor interventional therapy, which is made of a degradable or non-degradable material and is internally loaded with an anti-tumor vascular drug for resisting tumor vessels, tumor angiogenesis and tumor angiogenesis, and the drug comprises an antibody or small molecule compound drug. The growth of original blood vessels of tumor tissues and the angiogenesis of the tumor tissues can be resisted or inhibited, so that the formation of collateral circulation of the tumor tissues is inhibited, and the growth, metastasis and relapse of tumors are inhibited. According to the present invention, the tumor blood vessel is inhibited while the tumor tissue blood supply is embolized and blocked, the tumor angiogenesis and the tumor collateral circulation formation are inhibited, and the tumor recurrence and the tumor metastasis are effectively avoided. The anti-tumor vascular drug is slowly released in a tumor area, the high drug concentration can be kept at the tumor part for a long time, the drug concentration in systemic circulation is not too high, the drug utilization rate is increased, and the side effects of the drug are relatively reduced.
Owner:太阳雨林(厦门)生物医药有限公司

Tumor nucleic acid vaccine based on tissue factor as well as preparation method and application of vaccine

The invention discloses a tumor nucleic acid vaccine based on a tissue factor, wherein a plasmid is used as a vector; the plasmid is interpolated with a DNA sequence for coding HBc, and the sequence is interpolated with a DNA sequence for coding a human-source TF target epitope polypeptide; sequence of the human-source TF target epitope polypeptide is represented in SEQ ID NO: 1, and the polypeptide is amino acid at position 74-94 of human-source TF; and an ISS sequence is included in a non-coding region of the plasmid vector. Furthermore, the invention discloses a preparation method and an application of the tumor nucleic acid vaccine. The tumor nucleic acid vaccine, through genetic engineering means, presents a sequence selected from TF and including an epitope target point onto a reconstructed hepatitis B core antigen to construct an antigen epitope nucleic acid vaccine; the antigen epitope nucleic acid vaccine is applied to a body through intramuscular injection, so as to promote expression of polypeptide including a TF target epitope, and to stimulate active immunity of the body, thus preventing and treating tumors.
Owner:JIANGSU HIGH WIT BIOTECH CO LTD

Pharmaceutical composition of cortex fraxini extract and borneol as well as preparation method and application of pharmaceutical composition

The invention provides a pharmaceutical composition of a cortex fraxini extract and borneol as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises 3.6-116 parts by weight of the cortex fraxini extract and 1 part by weight of borneol. The cortex fraxini extract mainly takes cortex fraxini total coumarin as an active ingredient, and the cortex fraxini total coumarin comprises aesculin, aesculetin, fraxin and fraxetin; the content of cortex fraxini total coumarin in the cortex fraxini extract is 75-85 wt% or above, the sum of the contents of aesculin, aesculetin, fraxin and fraxetin in the cortex fraxini extract is 55-65 wt% or above, and the content ratio of aesculin to aesculetin to fraxetin is (30.0-40.0): (2.0-4.0): (20.0-30.0): 1. The cortex fraxini extract is prepared by taking traditional Chinese medicine cortex fraxini decoction pieces or a cortex fraxini medicinal material as a raw material and adopting a combined process of alcohol extraction, macroporous resin column purification and the like. The composition disclosed by the invention can be used for remarkably inhibiting the formation of newborn lymphatic vessels in corneas and has a relatively good treatment effect on diseases such as corneal injury.
Owner:SHANGHAI UNIV OF T C M

Il-33 antagonist-containing therapeutic agent for endometriosis

To provide a therapeutic agent for endometriosis and adenomyosis. IL-33 was identified as an exacerbating factor in endometriosis and adenomyosis, and an IL-33 antagonist, which is capable of inhibiting the function of IL-33, was found to be useful for treating, preventing or alleviating endometriosis and uterine adenomyosis.
Owner:MITSUBISHI TANABE PHARMA CORP +1

A fusion protein with functions of anti-tumor, anti-inflammation and treatment of ophthalmic diseases and its preparation method and application

The invention discloses fusion protein with anti-tumor, anti-inflammation and oculopathy-treatment functions and a preparation method and application thereof, which belong to the technical field of biological pharmacy. Specifically, the invention relates to the fusion protein of an integrin blocking agent, which has the function of inhibiting tumor angiogenesis and has the integrin affinity and the combining capacity. A rigid (R) or flexible (F) linker is adopted to fuse two polypeptides, so as to respectively obtain protein A and protein G, the medicine effect can be increased, the half-life period can be extended, the stability can be enhanced, and the fusion protein has the characteristics of strong action effect, low toxicity and the like and can be used for preventing and treating solid tumors, all kinds of inflammation and angiogenesis oculopathy. The fusion protein structurally comprises two angiogenesis inhibiting polypeptides and the amino acid linker between the two angiogenesis inhibiting polypeptides, and the fusion protein is expressed in colibacillus or eukaryocyte by using a genetic engineering method and is obtained through separation and purification of a GST (Glutathione S Transferase) affinity column.
Owner:CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products